Select a Size
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C4H6N4O3S2
CAS Number:
Molecular Weight:
222.25
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Product Name
Acetazolamide, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
SMILES string
CC(=O)Nc1nnc(s1)S(N)(=O)=O
InChI key
BZKPWHYZMXOIDC-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
acetazolamide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
Application
Carbonic anhydrase inhibitor; increases cerebral blood flow.
Biochem/physiol Actions
Inhibits water permeability of membranes by interacting with aquaporins
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Karine Auré et al.
Neurology, 81(21), 1810-1818 (2013-10-25)
To report that homoplasmic deleterious mutations in the mitochondrial DNA MT-ATP6/8 genes may be responsible for acute episodes of limb weakness mimicking periodic paralysis due to channelopathies and dramatically responding to acetazolamide. Mitochondrial DNA sequencing and restriction PCR, oxidative phosphorylation
Bradley A Edwards et al.
Sleep, 36(2), 281-285 (2013-02-02)
The magnitude of the post-apnea/hypopnea ventilatory overshoot following arousal may perpetuate subsequent respiratory events in obstructive sleep apnea (OSA) patients, potentially contributing to the disorder's severity. As acetazolamide can reduce apnea severity in some patients, we examined the effect of
Emma V Low et al.
BMJ (Clinical research ed.), 345, e6779-e6779 (2012-10-20)
To assess the efficacy of three different daily doses of acetazolamide in the prevention of acute mountain sickness and to determine the lowest effective dose. Systematic review and meta-analysis. Medline and Embase along with a hand search of selected bibliographies.
A S Vagal et al.
AJNR. American journal of neuroradiology, 30(5), 876-884 (2009-02-28)
The acetazolamide (ACZ) challenge test is a useful clinical tool and a reliable predictor of critically reduced perfusion. In patients with chronic steno-occlusive disease, the ability to maintain normal cerebral blood flow by reducing vascular resistance secondary to autoregulatory vasodilation
Bengt Kayser et al.
High altitude medicine & biology, 13(2), 82-92 (2012-06-26)
Acetazolamide is used to prevent acute mountain sickness (AMS). We assessed efficacy and harm of acetazolamide for the prevention of AMS, and tested for dose-responsiveness. We systematically searched electronic databases (until April 2011) for randomized trials comparing acetazolamide with placebo
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service